

# VRBPAC VOTING QUESTION # 1

---

Are the available data adequate to support the safety of AREXVY (RSVPreF3+AS01<sub>E</sub>) when administered to individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by RSV?

**Please vote “Yes” or “No”**

# VRBPAC VOTING QUESTION # 2

---

Are the available data adequate to support the effectiveness of AREXVY (RSVPreF3+AS01E) for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older?

**Please vote “Yes” or “No”**